Anti-VEGF monotherapy, such as Bevacizumab, an approved anti-tumor angiogenesis drug targeting VEGF, has shown a definite anti-tumor effect in a variety of malignant tumors, including NSCLCs [15,16,17,18]. Here, VEGFA is linked to cancer.